Intelligence Report · ~14 min read
Respiratory · Chronic Cough Competitive Landscape
7 findings · 46 signals · 11 insights
Type
Competitive Landscape ReportGenerated
Jul 23, 2026
Confidence
Moderate Confidence · 82%
Evidence
53 items
Sources
4
Executive Summary
Synthesized assessment from linked signals, findings, and evidence relationships.
Competitive landscape assessment for Respiratory · Chronic Cough synthesizes 7 Competitiva findings across 46 active signals. 1 high-pressure competitive threats identified. 6 companies maintain material exposure in this therapeutic area.
Key Developments
Material intelligence events ranked by strategic relevance.
- competitive
Roche — BLU-5937
Roche is a direct competitive threat because it is already approved in Respiratory · Chronic Cough (BLU-5937) and could narrow GSK's development lead.
View detail - competitive
Roche — BLU-5937
Roche is a direct competitive threat because it is already approved in Respiratory · Chronic Cough (BLU-5937) and could narrow GSK's development lead.
View detail - competitive
Bristol Myers Squibb — BLU-5937
Bristol Myers Squibb is an emerging emerging competitor with Phase I activity on BLU-5937 in Respiratory · Chronic Cough; while behind GSK (Phase III), accelerated readouts could compress GSK's strategic window.
View detail - competitive
AstraZeneca — Tozorakimab met OBERON/TITANIA primary endpoints
AstraZeneca is an emerging emerging competitor with Phase III activity on Tozorakimab met OBERON/TITANIA primary endpoints in Respiratory · COPD; while behind AstraZeneca (Phase III), accelerated readouts could compress AstraZeneca's strategic window.
View detail - competitive
AstraZeneca — Third tozorakimab positive Phase III in COPD
AstraZeneca is a direct competitive threat because it has a Phase III program in Respiratory · COPD (Third tozorakimab positive Phase III in COPD) and could narrow AstraZeneca's development lead.
View detail - competitive
AstraZeneca — Tozorakimab achieves primary endpoints in Phase III trials for COPD
AstraZeneca is a direct competitive threat because it has a Phase III program in Respiratory · COPD (Tozorakimab achieves primary endpoints in Phase III trials for COPD) and could narrow the signal sponsor's development lead.
View detail - competitive
Merck — European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the…
Merck is a regulatory competitive threat because recent agency-facing activity on European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the… in Respiratory · Asthma may reset approval benchmarks and timeline expectations for AstraZeneca.
View detail
Strategic Implications
Portfolio and competitive decisions informed by this intelligence profile.
Monitor 1 high-pressure competitive programs for portfolio displacement risk. Cross-reference 11 executive insights for synthesized strategic assessment. Leading competitive pressure: Medium across top-linked programs.
Supporting Evidence
Evidence-backed items with source attribution and confidence disclosure.
Roche — BLU-5937
73%Roche is a direct competitive threat because it is already approved in Respiratory · Chronic Cough (BLU-5937) and could narrow GSK's development lead.
Source: Roche
View evidenceRoche — BLU-5937
73%Roche is a direct competitive threat because it is already approved in Respiratory · Chronic Cough (BLU-5937) and could narrow GSK's development lead.
Source: Roche
View evidenceBristol Myers Squibb — BLU-5937
71%Bristol Myers Squibb is an emerging emerging competitor with Phase I activity on BLU-5937 in Respiratory · Chronic Cough; while behind GSK (Phase III), accelerated readouts could compress GSK's strategic window.
Source: Bristol Myers Squibb
View evidenceAstraZeneca — Tozorakimab met OBERON/TITANIA primary endpoints
91%AstraZeneca is an emerging emerging competitor with Phase III activity on Tozorakimab met OBERON/TITANIA primary endpoints in Respiratory · COPD; while behind AstraZeneca (Phase III), accelerated readouts could compress AstraZeneca's strategic window.
Source: AstraZeneca
View evidenceAstraZeneca — Third tozorakimab positive Phase III in COPD
95%AstraZeneca is a direct competitive threat because it has a Phase III program in Respiratory · COPD (Third tozorakimab positive Phase III in COPD) and could narrow AstraZeneca's development lead.
Source: AstraZeneca
View evidenceAstraZeneca — Tozorakimab achieves primary endpoints in Phase III trials for COPD
95%AstraZeneca is a direct competitive threat because it has a Phase III program in Respiratory · COPD (Tozorakimab achieves primary endpoints in Phase III trials for COPD) and could narrow the signal sponsor's development lead.
Source: AstraZeneca
View evidenceMerck — European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the…
77%Merck is a regulatory competitive threat because recent agency-facing activity on European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the… in Respiratory · Asthma may reset approval benchmarks and timeline expectations for AstraZeneca.
Source: Merck
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.
Signals
- FDA Approves TRIMBOW (NDA219622) by Chiesi
Regulatory Approval
- Resmed Astral Ventilators Face Serious Electrical Component Failure Risk
Safety Signal
- Baxter Issues Correction for Volera Positive Pressure Breathing Devices Due to Air Leakage
Safety Signal
- FDA Approves Supplemental Application for Breztri Aerosphere
Regulatory Approval
- Teva's Budesonide and Formoterol Fumarate Dihydrate Receives FDA Approval
Regulatory Approval
- AstraZeneca's PT010 Study Targets Severe Asthma in Adults and Adolescents
Trial Update
- MiNK Therapeutics Trials agenT-797 for Severe Pneumonia with AHRF
Trial Update
- Baxter's Volara System Faces Air Leak Issues Impacting Patient Therapy
Safety Signal
Insights
- Baxter's Volera Device Correction: Strategic Risks and Opportunities in Respiratory Market
Respiratory · Medical Devices
- Regulatory Approval of Rubicon's ANDA220869 Alters Cough and Cold Market Dynamics
Respiratory · Cough and Cold
- Regulatory and Safety Challenges Impacting Respiratory Device Market Dynamics
Respiratory · Device
- Amgen's AMG 691 Phase 1 Study: Strategic Implications for Asthma Market Positioning
Respiratory · Asthma
- Cipla's Albuterol Sulfate Approval: Implications for Market Dynamics
Respiratory · Bronchodilator
- Evaluating Budget Impact of Asthma Therapies in Saudi Arabia: Strategic Implications
Respiratory · Asthma
- Tezepelumab's EVOLVE Study: Key to Competitive Positioning in Severe Asthma
Respiratory · Asthma
- GSK's BLU-5937 Phase 3 Trial: A Pivotal Moment in Chronic Cough Treatment
Respiratory · Chronic Cough